Last edition
News about "Monte Rosa Therapeutics "
Monte Rosa Therapeutics Partners with Novartis on Degraders for Immune Diseases
Monte Rosa to receive an upfront payment of USD 120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory and sales milestones, as well as tiered royalties on global net sales.
Monte Rosa Therapeutics | 16/09/2025 | By Dineshwori | 203
Novartis has entered into a licensing agreement with Monte Rosa Therapeutics valued at up to 5.7 billion USD. The deal centres on developing medicines for immune-mediated diseases, where the immune system mistakenly attacks healthy tissue.
Monte Rosa Therapeutics | 15/09/2025 | By Darshana | 192
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy